G

a

MODIFIED ATTY DOCKET NO.: NMT-8440 SERIAL No. 10/716,929 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE APPLICANT(S): Rekha Bansal STATEMENT BY APPLICANT (Use several sheets if necessary) FILING DATE: November 19, 2003 **GROUP: 1644** NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) /PV/ Acioli, J.M., M. Isobe, and S. Kawasaki, "Early Complement System Activation and Neutrophil priming in Α acute pancreatitis: Participation of trypsin", Surgery 1997. 122(5) pp. 909-917 Arnaout, M.A., "Structure and function of the leukocyte adhesion molecules CD11/CD18". Blood, 1990. 75(5): p. 1037-50 Barnum, S.R., et al., "Expression of the complement C3a and C5a are increased in bronchoalveolar lavade /PV/ C fluid after segmental allergen provocation in subjects with asthma". Am J Respir Crit Care Med, 2001. 164(10 Pt 1): 1841-3. /PV/ D 71(1-2): p. 227-9. /PV/ Ε Neutrotrauma, 2001. 18(12): p. 1295-311. ABSTRACT ONLY /PV/ F /PV/ G Cardiothorac Surg, 1990. 4(6): p. 291-6 ABSTRACT ONLY

Basta, M., I. Illa, and M.C. Dalakas, "Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis". J Neuroimmunol, 1996. Bellander, B.M., et al., "Complement activation in the human brain after traumatic head injury". J Belmont, H.M., et al., "Complement activation during systematic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum, 1986, 29(9): p. 1085-9. Bonser, R.S., et al., "Complement activation before, during and after cardiopulmonary bypass". Eur J /PV/ Chenoweth, D.E., "Anaphylatoxin formation in extracorporeal circuits", Complement, 1986. 3(3): p. 152-65. ABSTRACT ONLY Η Davis, E.A., et al., "Inhibition of neutrophil adhesion and the membrane attack complex of complement /PV/ synergistically prolongs cardiac xenograft survival", J Heart Lung Transplant, 1995, 14(5): p 973-80. /PV/ del Balzo, U., M.J. Polley, and R. Levi, "Cardiac anaphylaxis. Complement activation as an amplification J system". Circ Res, 1989. 65(3):p.847-57. Fung, M., et al., Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal amibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg, 2001. 122(1). p. 113-22. /PV/ Furman, M.I., et al., Circulating monocyte-platelet aggregates are an early marker of acute myocardial L infarction. J Am Coll Cardiol, 2001, 38(4); p. 1002-6. Furman, M.I., et al., Increased platelet reactivity and circulating monocyte-platelet aggregates in patients /PV/ M with stable coronary artery disease. J Am Coll Cardiol, 1998. 31(2): p. 352-8. /PV/ Gerard, N.P. and C. Gerard, Complement in allergy and asthma. Curr Opin Immunol, 2002. 14(6): p. 705-8. Ν Gillinov, A.M., et al., Complement inhibition with soluble complement receptor type 1 in cardiopulmonary /PV/  $\bigcirc$ bypass. Ann Thorac Surg, 1993. 55(3): p. 619-24. ABSTRACT ONLY Gloor, B., et al., Predictive value of complement activation fragments C3a and sC5b-9 for development of /PV/ Р severe disease in patients with acute pancreatitis. Scand J Gastroenterol, 2003. **38**(10): p. 1078-82 Gong, J., et al., Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the /PV/ Q blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol, 1996. 16(4): ABSTRACT ONLY p. 222-9.

**EXAMINER** 

**DATE CONSIDERED** 

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIFIED (REV. 6-89)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY DOCKET NO.: NMT-8440

SERIAL NO. 10/716,929

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT** 

APPLICANT(S): Rekha Bansal

(Use several sheets if necessary)

FILING DATE: November 19, 2003 GROUP: 1644

## NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMI	NER	DATE CONSIDERED				
/PV/	Q	Mead, R.J., et al., The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol, 2002. <b>168</b> (1): p. 458-65. <b>ABSTRACT ONLY</b>				
/PV/	Р	Lin F. et al., Decay-Accelerating Factor Deficiency Increases Susceptibility to Dextran Sulfate Sodium-Induced Colitis: Role for Complement in Inflammatory Bowel Disease, Journal of Immunology 2004, 172:3836-3841				
/P <b>V</b> /	0	Lien, Y.H., L.W. Lai, and A.L. Silva, <i>Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice.</i> Life Sci, 2003. <b>74</b> (5): p. 543-52.				
/PV/	N	Langlois, P.F. and M.S. Gawryl, <i>Detection of the terminal complement complex in patient plasma following acute myocardial infarction.</i> Atherosclerosis, 1988. <b>70</b> (1-2): p. 95-105. <b>ABSTRACT ONLY</b>				
/PV/	М	Krug, N., et al., Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med, 2001. <b>164</b> (10 Pt 1): p. 1841-3.				
/PV/	L	Kirschfink, M., et al., [Significance of the complement system for xenotransplantation: strategies for therapeutic intervention]. Zentralbl Chir, 1998. 123(7): p. 793-7. ABSTRACT ONLY				
/PV/	K	Kaczorowski, S.L., et al., Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Metab, 1995. <b>15</b> (5): p. 860-4. ABSTRACT ONLY				
/PV/	J	Johnson, L.V., et al., Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res, 2001. <b>73</b> (6): p. 887-96. ABSTRACT ONLY				
/PV/	l	Humbles, A.A., et al., A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature, 2000. <b>406</b> (6799): p. 998-1001.				
/PV/	Н	Howard, R.J., et al., Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation. Arch Surg, 1988. <b>123</b> (12): p. 1496-501. <b>ABSTRACT ONLY</b>				
/PV/	G	Horigome, I., et al., <i>Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases</i> . Clin Exp Immunol, 1987. <b>70</b> (2): p. 417-24.				
/PV/	F	Hopkins, P., et al., <i>Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis.</i> Arthritis Rheum, 1988. <b>31</b> (5): p. 63241. <b>ABSTRACT ONLY</b>				
/PV/	Е	Holmes, J.H.t., et al., <i>Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes.</i> Inflamm Res, 2002. <b>51</b> (12): p. 579-86. <b>ABSTRACT ONLY</b>				
/PV/	D	Haeffner-Cavaillon, N., et al., <i>C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes.</i> J Immunol, 1987. <b>139</b> (3): p. 794-9.				
***************************************	C	Gupta-Bansal, R., J.B. Parent, and K.R. Brunden, <i>Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies.</i> Mol-Immunol, 2000. <b>37</b> (5): p. 101-201.				
000000000000000000000000000000000000000	***************************************	Grossklaus, C., et al., <i>Induction of platelet aggregation by the complement-derived peptides C3a and C5a.</i> Naunyn Schmiedebergs Arch Pharmacol, 1976. <b>295</b> (1): p. 71-6.				
******************************		and joint destruction in experimental arthritis. J Exp Med, 2002. <b>196</b> (11): p. 1461-71.				
		Grant, E.P., et al., Essential role for the C5a receptor in regulating the effector phase of synovial infiltration				

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIFIED
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

FILING DATE: November 19, 2003

GROUP: 1644

(Use several sheets if necessary)			FILING DATE: November 19, 2003	GROUP: 1644			
	NON	I-PATENT LITERATURE DOCUME	ENTS (Including Author, Title, Date, Pertin	nent Pages, Etc.)			
/PV/	Α	Meuer, S., et al., Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol, 1981. <b>126</b> (4): p. 1506-9. ABSTRACT ONLY					
/PV/	В	Mohr, R., et al., The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg, 1988. <b>96</b> (4): p. 530-4. <b>ABSTRACT ONLY</b>					
/PV/	С	Mullins, R.F., N. Aptsiauri, and G.S. Hageman, Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye, 2001. <b>15</b> (Pt 3): p. 390-5. <b>ABSTRACT ONLY</b>					
/PV/	D	Nataf, S., et al., Attenuation of experimental autoimmune demyelination in complement-deficient mice.  J Immunol, 2000. <b>165</b> (10): p. 5867-73. ABSTRACT ONLY					
/PV/	E	Pruitt, S.K., et al., <i>The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts.</i> Transplantation, 1994. <b>57</b> (3): p. 363-70. <b>ABSTRACT ONLY</b>					
/PV/	F	Rinder, C.S., et al., <i>Cardiopulmonary bypass induces leukocyte-platelet adhesion.</i> Blood, 1992. <b>79</b> (5): p. 1201-5. <b>ABSTRACT ONLY</b>					
/PV/	G	Rinder, C.S., et al., Role of C3 cleavage in monocyte activation during extracorporeal circulation.  Circulation, 1999. <b>100</b> (5): p. 553-8.  ABSTRACT ONLY					
/PV/	Н	Rinder, C.S., et al., <i>Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.</i> J Clin Invest, 1995. <b>96</b> (3): p. 1564-72.					
/PV/	1	Roxvall, L., A. Bengtson, and M. Heideman, <i>Anaphylatoxin generation in acute pancreatitis</i> . J Surg Res, 1989. <b>47</b> (2): p. 138-43. <b>ABSTRACT ONLY</b>					
/PV/	J	Roxvall, L.I., L.A. Bengtson, and J.M. Heideman, <i>Anaphylatoxins and terminal complement complexes in pancreatitis. Evidence of complement activation in plasma and ascites fluid of patients with acute pancreatitis.</i> Arch Surg, 1990. <b>125</b> (7): p. 918-21. <b>ABSTRACT ONLY</b>					
/PV/	К	Saatvedt, K., et al., Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest, 1995. <b>55</b> (1): p. 79-86. <b>ABSTRACT ONL</b> :					
/PV/	L	Schmid, E., et al., Requirement for C5a in lung vascular injury following thermal trauma to rat skin. Shock, 1997. 8(2): p. 119-24. ABSTRACT ONLY					
/PV/	М	Simpson, P.J., et al., Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest, 1988. 81(2): p. 624-9.					
/PV/	N	Stahel, P.F., M.C. Morganti-Kossmann, and T. Kossmann, <i>The role of the complement system in traumatic brain injury</i> . Brain Res Brain Res Rev, 1998. <b>27</b> (3): p. 243-56. <b>ABSTRACT ONLY</b>					
/PV/	0	Stahl, G.L., et al., <i>Role for the ai</i> Pathol, 2003. <b>162</b> (2): p. 449-55.	ole for the alternative complement pathway in ischemia/reperfusion injury. Am J ): p. 449-55. ABSTRACT ONLY				
/PV/	Р	Thurman, J.M., et al., Lack of a renal failure in mice. J Immunol,	of a functional alternative complement pathway ameliorates ischemic acute nunol, 2003. <b>170</b> (3): p. 1517-23. ABSTRACT ONLY				
/PV/	Q	Torzewski, J., et al., Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol, 1996. <b>16</b> (5): p. 673-7. <b>ABSTRACT ONLY</b>					
EXAMI	NER		DATE CONSIDERED				

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIFIED FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.: NMT-8440	0	SERIAL NO. 10/716,929		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT(S): Rekha Bansal				
(Use several sheets if necessary)			FILING DATE: November 19, 2	003	GROUP: 1644		
	NON-	PATENT LITERATURE DOCUME	NTS (Including Author, Title, D	ate, Pertinent F	Pages, Etc.)		
/PV/	Α	Undar, A., et al., Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass. Ann Thorac Surg, 2002. <b>74</b> (2): p. 355-62; discussion 362. <b>ABSTRACT ONLY</b>					
/PV/	В	van Beek, J., K. Elward, and P. Gasque, Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci, 2003. 992: p. 56-71. ABSTRACT ONLY					
/PV/	С	Vedeler, C.A., et al., Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barre syndrome and multiple sclerosis. J Neuroimmunol, 1996. <b>67</b> (1): p. 17-20.					
/PV/	D	Vickers, J., et al., Measurement of platelet activation and adhesion to leukocytes during haemodialysis.  Platelets, 1998. 9(3-4): p. 261-4. ABSTRACT ONLY					
/PV/	Е	Wan, K.C., et al., A longitudinal study of C3, C3d and factor Ba in burn patients in Hong Kong Chinese. Burns, 1998. <b>24</b> (3): p. 241-4.					
/PV/	F	Wang, Y., et al., Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A, 1995. <b>92</b> (19): p. 8955-9.					
/PV/	G	Ware, L.B. and M.A. Matthay, <i>The acute respiratory distress syndrome</i> . N Engl J Med, 2000. <b>342</b> (18): p. 1334-49.					
/PV/	Н	Yasuda, M., et al., <i>The complement system in ischemic heart disease.</i> Circulation, 1990. <b>81</b> (1): p. 156-63. ABSTRACT ONLY					
/PV/	I	Zhou, W., et al., <i>Predominant role for C5b-9 in renal ischemia/reperfusion injury.</i> J Clin Invest, 2000. <b>105</b> (10): p. 1363-71.					
/PV/	J	Ahlgren, E., et al., Neurocognitive impairment and driving performance after coronary artery bypass surgery. Eur J Cardiothorac Surg, 2003. 23(3): p. 334-40. ABSTRACT ONLY					
***************************************		Ann Thorac Surg. 1994 Mar;57(3):781-3, P.C.a.a.C.a.c.d.c.b.M.P., Chello M, Marchese AB.)					
000000000000000000000000000000000000000	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Arrowsmith, J.E., et al., <i>Central nervous system complications of cardiac surgery</i> . Br J Anaesth, 2000. <b>84</b> (3): p. 378-93.					
/PV/	M	Cecic, I., J. Sun, and M. Korbelik, <i>Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells.</i> Photochem Photobiol, 2006. <b>82</b> (2): p. 558-62. <b>ABSTRACT ONLY</b>					
/PV/	N	Keith, J.R., et al., Assessing postoperative cognitive change after cardiopulmonary bypass surgery. Neuropsychology, 2002. <b>16</b> (3): p. 411-21.					
*******************************		Larsson, R., et al., Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete					
		abrogation of binding of PMNs to the biomaterial surface. Immunopharmacology, 1997. <b>38</b> (1-2): p. 119-27.					
/PV/	Р	Levy, J.H. and K.A. Tanaka, <i>Inflammatory response to cardiopulmonary bypass</i> . Ann Thorac Surg, 2003. <b>75</b> (2): p. S715-20.					
/PV/	Q	Mahanna, E.P., et al., <i>Defining neuropsychological dysfunction after coronary artery bypass grafting.</i> Ann Thorac Surg, 1996. <b>61</b> (5): p. 1342-7.					
EXAMINER DATE CONSIDERED							
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609;							

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

					Sneet 5 of 5	
MODI FORM (REV. 6	PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKE	T NO.: NMT-8440	SERIAL NO. 10/716,929	
		MATION DISCLOSURE EMENT BY APPLICANT	APPLICANT(S): Rekha Bansal			
(Use several sheets if necessary)			FILING DATE	: November 19, 2003	GROUP: 1644	
	NON-	-PATENT LITERATURE DOCUMI	ENTS (Includin	g Author, Title, Date, Pertinent I	Pages, Etc.)	
/PV/	Α	Neumann, E., et al., <i>Local production of complement proteins in rheumatoid arthritis synovium.</i> Arthritis Rheum, 2002. <b>46</b> (4): p. 934-45. <b>ABSTRACT ONLY</b>				
/PV/	В	Newman, M.F., Kirchner J.L., Phillips-Bute B., Longitudinal assessment of neurocognitive function after cornary artery bypass surgery. N Engl J Med, 2001. <b>344</b> : p. 395-402.				
900000000000000000000000000000000000000		Nilsson B, L.R., Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD., Compstatin inhibits complement				
		1;92(5):1661-7.		<u> </u>		
/PV/	D	Rinder, C.S., et al., Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg, 1999. <b>118</b> (3): p. 460-6.				
/PV/	E	Selnes, O.A. and G.M. McKhann, <i>Neurocognitive complications after coronary artery bypass surgery</i> . Ann Neurol, 2005. <b>57</b> (5): p. 615-21. <b>ABSTRACT ONLY</b>				
000000000000000000000000000000000000000	0000000000 <del>0000000000</del>	Selnes, O.A., et al., <i>Cognitive an</i> Clin, 2006. <b>24</b> (1): p. 133-45.	d neurobehavio	ral dysfunction after cardiac bypa	ss procedures. Neurol	
	G					
	H					
	l					
	J					
	К					
	∟					
	М					
	Z					
	0					
	Р					
	Q					
EXAMINER /F Pierre Vandervegt/ DATE CONSIDERED 03/28/2008						

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.